

Uzman Dr. İzzet DOĞAN

Kişisel Bilgiler

E-posta: izzet.dogan@istanbul.edu.tr

Uluslararası Araştırmacı ID'leri

ORCID: 0000-0003-1018-1119

ScopusID: 54888517400

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases**
Kahraman S., Karakaya S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., HAMDARD J., Yildirim S., Dogan T., Isik S., et al.
Scientific Reports, cilt.14, sa.1, 2024 (SCI-Expanded)
- II. **Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer**
Khanmammadov N., Doğan I., Okay N. S., AZİZY A., Saip P., AYDINER A.
Medicine (United States), cilt.103, sa.1, 2024 (SCI-Expanded)
- III. **Single-agent temozolomide as salvage therapy in heavily pretreated metastatic sarcoma patients**
Dogan I., Paksoy N., BAŞARAN M.
Journal of Cancer Research and Therapeutics, cilt.20, sa.1, ss.93-97, 2024 (SCI-Expanded)
- IV. **The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients**
Ak N., Tuz Z., Aydin E., Ferhatoğlu F., SARI M., Paksoy N., Doğan I., Yildiz A., Dişçi R., Saip P. M.
Turkish Journal of Medical Sciences, cilt.54, sa.1, ss.229-238, 2024 (SCI-Expanded)
- V. **Outcomes of the patients with metastatic male breast cancer**
Dogan I., Khanmammadov N., ÖZKURT S., AYDINER A., Saip P.
Journal of Cancer Research and Therapeutics, cilt.20, sa.1, ss.98-102, 2024 (SCI-Expanded)
- VI. **Efficacy and safety of sorafenib in adult metastatic osteosarcoma patients**
Dogan I., PAKSOY N., BAŞARAN M.
Journal of Cancer Research and Therapeutics, cilt.20, sa.3, ss.979-983, 2024 (SCI-Expanded)
- VII. **Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression**
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Saip P., AYDINER A.
Scientific Reports, cilt.13, sa.1, 2023 (SCI-Expanded)
- VIII. **Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients**
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoğlu F., AK N., Emiroglu S., İBİŞ K., Onder S., Tukenmez M., et al.
Journal of Cancer Research and Clinical Oncology, cilt.149, sa.16, ss.14833-14841, 2023 (SCI-Expanded)
- IX. **Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center**
Khanmammadov N. A., Paksoy N., DOĞAN İ., Ferhatoğlu F., Saip P., Aydiner A.
Medicine, cilt.102, sa.39, 2023 (SCI-Expanded)
- X. **Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective**

Multicenter Registry Study of the Turkish Oncology Group

DOĞAN İ., AKSOY S., Cakar B., BAŞARAN G., Ercelep O., Molinas Mandel N., KORKMAZ T., Gokmen E., Sener C., AYDINER A., et al.

Cancers, cilt.15, sa.6, 2023 (SCI-Expanded)

- XI. **Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma**
DOĞAN İ., Iribas A., Ahmed M. A., Basaran M.
JOURNAL OF CHEMOTHERAPY, cilt.35, sa.4, ss.343-347, 2023 (SCI-Expanded)
- XII. **Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience**
TAŞTEKİN D., Paksoy N., DOĞAN İ., Ferhatoglu F., KHANMAMMADOV N., Bozbey H. U., KARABULUT S.
Journal of cancer research and therapeutics, cilt.19, sa.2, ss.253-258, 2023 (SCI-Expanded)
- XIII. **High-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience**
PAKSOY N., FERHATOĞLU F., DOĞAN İ., KHANMAMMADOV N., Iribas Celik A., Gulbas Z., BAŞARAN M.
Medicine (United States), cilt.101, sa.49, 2022 (SCI-Expanded)
- XIV. **Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group**
Erol C., Nahit Sendur M. A., Bilgetekin I., Garbioglu D. B., Hamdard J., Akbas S., Hizal M., Arslan C., Sevinc A., Kucukarda A., et al.
Journal of cancer research and therapeutics, cilt.18, 2022 (SCI-Expanded)
- XV. **Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study**
PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., AYDINER A.
Medicine (United States), cilt.101, sa.45, 2022 (SCI-Expanded)
- XVI. **The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study**
Dogan I., Ayhan M., Gurbuz M., Kucukarda A., Aydın E., ÜRÜN Y., ÇİÇİN İ., Saip P.
MEDICINE, cilt.101, sa.35, 2022 (SCI-Expanded)
- XVII. **Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer**
DOĞAN İ., Karabulut S., Tastekin D., Ferhatoglu F., Paksoy N., Sakar B.
JCPS-P-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, cilt.32, sa.8, ss.1014-1019, 2022 (SCI-Expanded)
- XVIII. **Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC**
DOĞAN İ., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., DEMİRKAZIK A., Aydinler A.
MEDICINE, cilt.101, sa.34, 2022 (SCI-Expanded)
- XIX. **Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors**
DOĞAN İ., Tastekin D., Karabulut S., Sakar B.
JOURNAL OF DIGESTIVE DISEASES, cilt.23, ss.493-499, 2022 (SCI-Expanded)
- XX. **The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study**
Ozdemir O., Zengel B., Yildiz Y., Uluc B. O., ÇABUK D., Ozden E., Salim D. K., PAYDAŞ S., Demir A., Diker O., et al.
ANTI-CANCER DRUGS, cilt.33, sa.7, ss.663-670, 2022 (SCI-Expanded)
- XXI. **Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.**
Dogan I., Paksoy N., Ak N., Vatansever S., Saip P., Aydinler A.
JOURNAL OF CLINICAL ONCOLOGY, cilt.40, sa.16, 2022 (SCI-Expanded)

- XXII. **Does nutritional status affect treatment tolerability, chemotherapy response and survival in metastatic gastric cancer patients? Results of a prospective multicenter study in Turkey**
Karabulut S., DOĞAN İ., USUL AFŞAR Ç., Karabulut M., Ak N., Duran A., Tastekin D.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.28, sa.1, ss.127-134, 2022 (SCI-Expanded)
- XXIII. **Prognostic value of FDG PET-CT in suspected recurrence of colorectal carcinoma: survival outcomes of a 10-year follow-up : FDG PET in recurrent colorectal CA.**
ozkan Z. G., Has Simsek D., Kuyumcu S., Oflas M., Isik E. G., Dogan I., Karabulut S., Sanli Y.
Annals of nuclear medicine, cilt.36, sa.1, ss.52-60, 2022 (SCI-Expanded)
- XXIV. **FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer**
Ay S., Atci M. M., Arikan R., Dulgar O., Ozyukseler D. T., Paksoy N., DOĞAN İ., ÖZTOSUN B., Tastekin D., Oven B. B., et al.
JOURNAL OF CHEMOTHERAPY, cilt.34, sa.7, ss.465-471, 2022 (SCI-Expanded)
- XXV. **Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study**
Bilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., BAŞOĞLU TÜYLÜ T., Ilhan A., Akdeniz N., Gulmez A., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.147, sa.7, ss.2145-2152, 2021 (SCI-Expanded)
- XXVI. **Efficacy of temozolomide in pretreated patients with metastatic sarcoma.**
Paksoy N., Dogan I., Ekenel M., Basaran M.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 (SCI-Expanded)
- XXVII. **Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.**
Aydiner A., Dogan I., Khanmammadov N., Saip P., Vatansever S.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 (SCI-Expanded)
- XXVIII. **Long-term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer.**
Dogan I., Aydin E., Paksoy N., Ferhatoglu F., Ak N., Ibis K., Onder S., Tukenmez M., Cabioglu N., Muslumanoglu M., et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 (SCI-Expanded)
- XXIX. **Efficacy of vincristine, irinotecan, and temozolomide (VIT) combination in adult patients with metastatic Ewing sarcoma.**
Dogan I., Iribas A., Ekenel M., Basaran M.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 (SCI-Expanded)
- XXX. **Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma.**
Paksoy N., Dogan I., Ekenel M., Basaran M.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 (SCI-Expanded)
- XXXI. **Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors.**
Ferhatoglu F., Paksoy N., Dogan I., Ak N., Pehlivan M., Ekenel M., Basaran M.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 (SCI-Expanded)
- XXXII. **Comparison of clinicopathological features in BRCA-wild type and -mutated male breast cancer patients**
Dogan I., Aydin E., Yazici H., Saip P.
CANCER RESEARCH, cilt.81, sa.4, 2021 (SCI-Expanded)
- XXXIII. **Outcomes of metastatic male breast cancer**
Dogan I., Khanmammadov N., Aydiner A., Saip P.
CANCER RESEARCH, cilt.81, sa.4, 2021 (SCI-Expanded)
- XXXIV. **Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer**
Dogan I., Aydin E., Khanmammadov N., Aydiner A., Saip P.
CANCER RESEARCH, cilt.81, sa.4, 2021 (SCI-Expanded)

- XXXV. **Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.**
Dogan I., Iribas A., Paksoy N., Ekenel M., Vatansever S., Basaran M.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.6, 2021 (SCI-Expanded)
- XXXVI. **A retrospective multicenter study: Clinicopathological factors affecting recurrence-free survival in operable gastric cancer patients.**
Yekeduz E., Dogan I., AKBULUT H., Karabulut S., Utkan G., ÜRÜN Y.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021 (SCI-Expanded)
- XXXVII. **Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.**
Dogan I., Tastekin D., Karabulut S., Sakar B.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

- I. **Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients**
Dogan I., Yıldız A., Ahmed M. A., Vatansever S.
Indian Journal of Surgical Oncology, cilt.15, sa.3, ss.489-494, 2024 (ESCI)
- II. **Efficacy of Bevacizumab-Based Therapy in Patient With Metastatic or Recurrent Cervical Cancer: Real Life Data**
KHANMAMMADOV N., Dogan I., okay n. s., Ugar M., Osmanova N., Saip P., Aydiner A.
Selçuk Tıp Dergisi, cilt.40, sa.2, ss.68-73, 2024 (Hakemli Dergi)
- III. **Hormonal Therapy in Pretreated Patients With Recurrent Ovary Granulosa Cell Tumor**
DOĞAN İ., Aydın E., Topuz S., Saip P., Salihoglu M. Y., Aydiner A.
JOURNAL OF PHARMACY PRACTICE, cilt.37, sa.1, ss.146-150, 2024 (ESCI)
- IV. **Evaluation of the Efficacy of Bevacizumab-based Therapies in Patients with Platinum-Resistant or Allergic Metastatic Ovarian Cancer**
Khanmammadov N., Doğan İ., Okay N. S., YILDIZ A., Khishigsuren B., AZİZY A., Saip P., AYDINER A.
Turk Onkoloji Dergisi, cilt.39, sa.2, ss.176-182, 2024 (ESCI)
- V. **The Effect of Adjuvant Therapies for Recurrence in Stage I Breast Cancer Patients: A Single Centre Experience**
Doğan İ., Khanmammadov N., Aydın E., PAKSOY N., Ferhatoğlu F., AK N., Emiroğlu S., İBİŞ K., Önder S., Tükenmez M., et al.
Turk Onkoloji Dergisi, cilt.39, sa.3, ss.257-264, 2024 (ESCI)
- VI. **Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors**
DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.
Eurasian Journal of Pulmonology, cilt.25, sa.1, ss.27-32, 2023 (Hakemli Dergi)
- VII. **Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine**
DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.
European Journal of Breast Health, cilt.19, sa.2, ss.128-133, 2023 (Scopus)
- VIII. **Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study**
Paksoy N., KHANMAMMADOV N., DOĞAN İ., Ferhatoğlu F., AHMED M. A., Karaman S., AYDINER A.
Medicine (Spain), cilt.102, sa.5, 2023 (Scopus)
- IX. **Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study**
Yekeduz E., Dogan I., Kaya D. M., Ozgur I., UTKAN G., Vatansever S., DEMİRCİ S., AKBULUT H., ÜRÜN Y.
JOURNAL OF GASTROINTESTINAL CANCER, cilt.53, sa.4, ss.870-879, 2022 (ESCI)
- X. **Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male**

Breast Cancer Patients

DOĞAN İ., Aydın E., Yazici H., Saip P.

EUROPEAN JOURNAL OF BREAST HEALTH, cilt.18, sa.4, ss.323-328, 2022 (ESCI)

- XI. **Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib**
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S.
CLINICAL CANCER INVESTIGATION JOURNAL, sa.4, ss.5-9, 2022 (ESCI)
- XII. **Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience**
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S.
CLINICAL CANCER INVESTIGATION JOURNAL, sa.3, ss.25-29, 2022 (ESCI)
- XIII. **Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib**
Dogan I., Khanmammadov N., Paksoy N., Ferhatoglu F., Aydın E., Vatansever S., Aydine A.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, cilt.37, ss.413-418, 2022 (ESCI)
- XIV. **The relationship between clinicopathological parameters and PD-L1 expression level in advanced stage non-small cell lung cancer**
Gurbuz M., DOĞAN İ., AKKUŞ E., ÖZAKINCI H., Tolunay P. K., KALACI E., BAĞLAN T., KÖKSOY E. B., CEYHAN K., SAK S., et al.
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, cilt.70, sa.2, ss.132-140, 2022 (ESCI)
- XV. **Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study**
Paksoy N., Ferhatoglu F., DOĞAN İ., Khanmammadov N., Bozbey H. U., KARABULUT S., Tastekin D.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, cilt.37, sa.4, ss.478-483, 2022 (ESCI)
- XVI. **Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma**
Naziye A. K., Paksoy N., Ferhatoglu F., Aydın E., Dogan I., Bektas E., Karaca M., Oguz Soyduinc H., Minareci Y., Sozen H., et al.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, cilt.36, ss.438-445, 2021 (ESCI)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.**
Khanmammadov N., DOĞAN İ., Saip P., Aydiner A.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023
- II. **iRECIST, irRC and irRECIST: A Pairwise Agreement and Performance Evaluation Study**
Kızıldağ Yırgın İ., Doğan İ., Vatansever S., Ertürk Ş. M.
RSNA2020, Illinois, Amerika Birleşik Devletleri, 24 - 29 Kasım 2020, ss.988
- III. **Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma**
Gurbuz M., DOĞAN İ., Utkan G., TAŞ F.
ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 Kasım 2020, cilt.31
- IV. **Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience**
DOĞAN İ., AYDIN E. M., AK N., İBİŞ K., Sukruoglu Ö., Erciyas S., YAZICI H., AYDINER A., SAİP P. M.
ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 Kasım 2020, cilt.31
- V. **BAĞIŞIKLIK KONTROL NOKTASI İNHİBİTÖRLERİ: İRECIST, İRRC VE İRRECIST'İN PERFORMANSLARININ VE UYUMLARININ DEĞERLENDİRİLMESİ IMMUNE CHECKPOINT İNHİBİTÖR: ASSESSMENT OF THE PERFORMANCE AND THE AGREEMENT OF İRECIST, İRRC AND İRRECIST**
Kızıldağ Yırgın İ., Doğan İ., Vatansever S., Ertürk Ş. M.
41.Ulusal Radyoloji Kongresi, Antalya, Türkiye, 24 Ekim - 01 Kasım 2020, ss.205-206

Metrikler

Yayın: 58

Atıf (WoS): 12

Atıf (Scopus): 19

H-İndeks (WoS): 1

H-İndeks (Scopus): 3